Liver cancer radiation and immune response study
Part of Cancer, Digestive system clinical trials.
This trial studies how radiation therapy affects the immune system and outcomes in people with liver cancer. It may help doctors understand better ways to treat the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with liver cancer (HCC) that is confirmed by either a biopsy or special imaging scans.
- You must be 18 years or older and able to understand and sign a consent form.
- You should be able to care for yourself most of the day (ECOG score 0-2).
- Your liver function must be in a certain range (Child-Pugh score 5 to 9) within the last month.
- You need to know your hepatitis B and C status (testing can be done).
- Your cancer should not have spread to distant organs that can't be treated with radiation.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests adding two immunotherapy and anti-angiogenesis drugs (atezolizumab and bevacizumab) to standard photon radiation for people with liver cancer that cannot be surgically removed. It aims to see if this combination can shrink tumors and improve outcomes.
This study tests proton beam radiation for people with liver cancer that is still inside the liver but cannot be treated with surgery or a small-needle procedure. Proton beams aim to better target the tumor while reducing radiation to nearby organs.
This trial tests a combination of liver-directed radiation therapy, an immunotherapy drug (which helps your immune system fight cancer), and a drug that blocks blood vessel growth to the tumor. It is for people with advanced liver cancer that cannot be treated with surgery.
This trial tests a combination of radiation therapy with two drugs (QL1706 and bevacizumab) for people with liver cancer that hasn't spread to other parts of the body but can't be surgically removed. The goal is to see if this approach can shrink or control the tumor.
This trial tests a combination of targeted radiation (photon radiotherapy) with two immunotherapy drugs (tremelimumab and durvalumab) for people with intermediate or advanced liver cancer that can't be surgically removed. The goal is to see if this combination can shrink tumors and improve outcomes.
This trial tests combining proton beam radiation with two immunotherapy drugs (tremelimumab and durvalumab) for people with intermediate or advanced liver cancer (HCC) that cannot be removed by surgery. The goal is to see if this combination can shrink tumors and improve outcomes.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.